Archives202520242023202220212020201920182017201620152014201320122011 May 29, 2018Further Analysis from its Pivotal Phase III Trial of Lupuzor™ in Patients with Systemic Lupus Erythematosus (SLE) Shows Positive Results in the Europe Cohort<sup>1</sup> Read More April 24, 2018Holding in company Read More April 23, 2018Immupharma PLC confident on Lupuzor’s™ future Read More April 19, 2018Holding in company Read More April 18, 2018Holding in company Read More April 17, 2018Top line results of Lupuzor™ Pivotal Phase III Trial Read More March 28, 2018Appointment of Joint Broker Read More March 23, 2018Lupuzor™ ‘database lock’ confirmed for 6 April 2018 Read More February 15, 2018London Investor Evening – Monday 26 February 2018 @ 6pm Read More February 08, 2018Holding in Company Read More February 05, 2018Notification of Major Interest – Lanstead Increases Holding to over 5% Read More January 24, 2018Successful Placing to Raise £10 Million Read More 1…1415161718…24
May 29, 2018Further Analysis from its Pivotal Phase III Trial of Lupuzor™ in Patients with Systemic Lupus Erythematosus (SLE) Shows Positive Results in the Europe Cohort<sup>1</sup> Read More
